Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ertugliflozin - Merck/Pfizer

Next Previous
Drug Profile

Ertugliflozin - Merck/Pfizer

Alternative Names: MK-8835; PF-04971729; PF-4971729; STEGLATRO

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Merck & Co; Pfizer
  • Class Antihyperglycaemics; Chlorobenzenes; Glycosides; Heterocyclic bicyclo compounds; Phenyl ethers; Small molecules
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Discontinued Hypertension

Most Recent Events

  • 11 Apr 2025 Merck and Pfizer complete a phase III trial in Type 2 diabetes mellitus (In children, In adolescents) in Belgium, France, Poland, Hungary, USA, Canada, Colombia, Costa Rica, Dominican Republic, Guatemala, Israel, Italy, Mauritius, Malaysia, Mexico, Philippines, Russia, Saudi Arabia, Turkey, Ukraine, United Arab Emirates, United Kingdom (PO) (NCT04029480) (EUCT2017-003455-35)
  • 30 Apr 2023 Merck and Seoul National University Bundang Hospital completes the phase III ERTU-GLS trial in Type-2 diabetes mellitus (Adjunctive treatment, In adults, In the elderly) in South Korea (NCT03717194)
  • 03 Jun 2022 Efficacy data from the phase III VERTIS CV trial in Type 2 diabetes mellitus presented at the 82nd Annual Scientific Sessions of the American Diabetes Association (ADA-2022)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top